eli lilly oral glp 1 is now pharma's top revenue company. It just got FDA approval for an GLP-1, but Wall Street isn't celebrating Eli Lilly Gets Speedy FDA

These patches are made for people who want a simpler way to stay on track

doi: 10.1074/jbc.272.34.21201

Decembers updates reflect the normal evolution of the GLP-1 field: new formulations, expanded coverage, and refined understanding of how to optimize outcomes

Insurance premiums are pooled costs

Once these therapeutics are covered by insurance, they tend to blow up budgets

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025